What is OCUL's market cap?

$1.57B, based on the Nov 4 close of $7.14.

Does Ocular Therapeutix pay a dividend?

No regular cash dividend has been paid in the last year.

How much of OCUL is sold short?

28.8M shares, 15.1% of float, as of Oct 15, 2026.

What sector is OCUL in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · OCULHealthcarePharmaceuticals

Ocular Therapeutix, Inc. (OCUL)

$7.14+4.69%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$7.10▼ 37.77% in range

Nov 3, 2025Low $6.29 · High $16.11Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Ocular Therapeutix closed at $7.14 on Nov 4, up 4.69%, 55.7% below its 52-week closing high. Volume of 3.4M shares was 1.17× its 20-day average (close to normal).

Split-adjusted performance: -2.7% over one month, -26.5% over six months, -37.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $13.47M, up 0.1% from a year earlier, with a net margin of -584.5%.

Short interest was 28.8M shares at the Oct 15 settlement, down 2.2% from the prior report (15.1% of float, 8.1 days to cover).

Market cap$1.57B219.6M shares

Revenue · quarter$13.5M+0.1% YoY

Diluted EPS$-0.35—

P/E · TTM—P/S 30.1×

Net margin-584.5%Gross 85.1%

Dividend yieldNone

52-week range6.29 – 16.11−55.7% from high

Volume3.4M1.17× 20-day avg

Volatility · 60d75.4%Annualised

Short % of float15.1%8.1 days to cover

Net cash$525.8MCash $598.6M

Next earnings—Not scheduled

Split-adjusted performance

1W −2.1%1M −2.7%3M −18.3%6M −26.5%YTD −41.2%1Y −37.4%3Y +189.1%5Y +5.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum49

Revenue growth42

Net margin29

Value (low P/E)—

Size77

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short28.8M−2.2% vs prior

Days to cover8.1Settled Oct 15

% of float15.1%

Short vol. 10d49.0%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
OCULOcular Therapeutix	$7.14	+4.69%	−26.5%	+0.1%	−584.5%	—	$1.57B
QUREuniQure	$23.03	−3.52%	+0.9%	+11.0%	−1387.8%	—	$1.60B	Compare
INVAInnoviva	$21.26	+1.58%	−5.6%	+19.3%	−69.8%	4.3	$1.54B	Compare
PAHCPhibro Animal Health	$39.43	+4.73%	−32.6%	+4.8%	5.5%	16.1	$1.60B	Compare
MLYSMineralys Therapeutics	$17.00	+6.32%	−43.6%	—	—	—	$1.50B	Compare
SUPNSupernus	$28.21	+0.21%	−45.2%	+18.0%	9.2%	—	$1.64B	Compare
ANIPANI Pharmaceuticals	$71.65	−0.87%	−14.8%	+25.9%	8.6%	16.5	$1.65B	Compare
KLRAKailera Therapeutics	$12.80	+1.75%	—	—	—	—	$1.66B	Compare
NUVBNuvation Bio	$4.73	+0.85%	−6.2%	+555.6%	−198.3%	—	$1.66B	Compare

News about Ocular Therapeutix

All news →

Ocular Therapeutix™ to Participate in July Scientific and Investor ConferencesGlobeNewswire Inc. · Jul 1, 2026▲ Positive Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool · Jun 15, 2026▲ Positive What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for InvestorsThe Motley Fool · May 19, 2026▼ Negative Ocular Therapeutix™ to Host Investor Day on June 17, 2026GlobeNewswire Inc. · Apr 22, 2026▲ Positive Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026GlobeNewswire Inc. · Feb 13, 2026▲ Positive

Quick answers

What does Ocular Therapeutix do?: Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye.
What is OCUL's market cap?: $1.57B, based on the Nov 4 close of $7.14.
Does Ocular Therapeutix pay a dividend?: No regular cash dividend has been paid in the last year.
How much of OCUL is sold short?: 28.8M shares, 15.1% of float, as of Oct 15, 2026.
What sector is OCUL in?: Healthcare, in the Pharmaceuticals industry.

About Ocular Therapeutix

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

HQ: Bedford, MA325 employeesListed Jul 25, 2014ocutx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology